CytomX highlights Varseta-M EpCAM Topo-1 ADC data in late-line metastatic colorectal cancer presentation

• CytomX presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting its Probody masked-therapeutics platform and oncology pipeline.
• Varsetatug masetecan (Varseta-M), an EpCAM-directed Topo-1 ADC, showed confirmed ORR of 20% at 8.6 mg/kg, 32% at 10 mg/kg in late-line CRC.
• Preliminary PFS measured 6.8 months at 8.6 mg/kg, 7.1 months at 10 mg/kg; FDA Fast Track granted for relapsed/refractory mCRC.
• Safety update cited manageable adverse events; diarrhea was the most common Grade 3 TRAE at 24%, falling to 10% in dose-optimization with prophylaxis.
• Cash totaled $330 million as of Q2 2026; runway projected into the second half of 2028; additional $37 million received from Regeneron.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.